Senior Data Scientist, BigHat Biosciences
Discovery Biology
Antibody discovery & engineering platform
Job no longer available
Antibody discovery & engineering platform
21-100 employees
Job no longer available
21-100 employees
Company mission
To improve human health by making it far easier to design advanced, next-generation antibody therapeutics.
Role
Who you are
- PhD in relevant domain [Computational Biology, Biology, Chemistry, Bioinformatics, Bioengineering, or similar] with 3+ years of industry experience preferred
- Experience with whole-genome sequence data, bulk and single-cell RNAseq data, and protein expression data including working with public data sources (e.g. TCGA, Human Protein Atlas, Human Cell Atlas, GTEx), and identifying gene signatures of disease
- Experience working with cancer genomics data, particularly tumor-associated antigen expression
- Strong knowledge of the data science toolkit, including: classic statistical models (regression, ANOVA, random effects models), statistical testing, interactive data visualization in python/R or React, and AI/ML techniques (SVMs, deep learning)
- Proficient in Python, R, or similar programming languages
- Proficient with cloud computing infrastructure like AWS and with version control like Github or Gitlab
- Excellent communication skills, experience interacting with diverse scientific teams
- The experience and judgment to operate/make key technical decisions independently
- Enjoys a fast-paced environment and executing across multiple projects
What the job involves
- Development of novel statistical/ML methods that leverage a range of unique data types from the BigHat platform, our partners, and public sources to drive decisions on therapeutic target selection
- Identification and triage of therapeutic targets from bulk tissue and single-cell whole-genome sequencing, transcriptomic and proteomic data
- Prioritization of potential protein targets based on assessment of biological and clinical evidence, viability, and alignment with BigHat’s unique platform
- Identification of areas of major therapeutic opportunity across a diverse set of diseases
- Leading computational and bioinformatic analyses that support the identification, development and assessment of therapeutic programs at BigHat
- Collaborating with scientists and program leads to quickly design, execute, and analyze experiments on the BigHat platform that guide our therapeutic programs
Our take
Melding genetics and code, BigHat Biosciences is a protein therapeutics company that develops antibodies for the medical industry using machine learning and AI. Established in 2019, the company combines advanced computational models with an automated wet lab to design and test antibody therapies more quickly than traditional methods. Its technology has been applied to a range of use cases too, including efforts during the pandemic to accelerate vaccine and therapeutic development.
The platform has particular value in helping develop treatment for complex and hard-to-treat diseases such as Alzheimer's disease, where designing effective biologic drugs is especially challenging. To support this work, BigHat has partnered with major pharmaceutical companies including Merck & Co, and Amgen to apply its AI-driven antibody design platform to drug discovery and development.
More recently, BigHat has continued to expand its partnerships and pipeline as interest in AI-enabled drug discovery grows. The company has also collaborated with Eli Lilly and Company to help develop next-generation antibody therapeutics using its Milliner platform, while also advancing its own internal programmes in areas such as oncology. With candidates including a gastrointestinal cancer and antibody-drug conjugate expected to enter clinical trials in 2026, BigHat is positioning itself not only as a technology partner for pharmaceutical companies but as as developer of its own next-generation biologic medicines.
Kirsty
Company Specialist at Welcome to the Jungle
Company
Funding (last 2 of 3 rounds)
Jul 2022
$75m
SERIES B
Feb 2021
$19m
SERIES A
Total funding: $99.3m
Company benefits
- Culture of excellence and growth
- Swift promotions with clear standards
- Autonomy and responsibility
- Fair compensation and recognition
- True work life balance
Company HQ
Beresford Park, San Mateo, CA
Leadership
Peyton Greenside
(Co-Founder, CEO & President)Peyton originally served as the CSO at BigHat before moving into the role of CEO in 2025. Previously, she was a Founding Scientific Advisor at VALIS.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
View 2 more jobs at BigHat Biosciences